BATAR: Individuals Currently Taking Boosted Atazanavir as Part of an HIV Treatment Regimen Will be Evaluated to See if Substituting Raltegravir for Nucleoside Transcriptase Inhibitors Will be Safe and Well Tolerated.

Exclusion Criteria

• •Prior exposure to raltegravir or elvitegravir
• •Women who are pregnant, breast-feeding, or with a positive pregnancy test
• •Sexually active fertile men not using effective birth control if their female partners are of child-bearing potential
• •Women of child-bearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for up to 8 weeks after the last dose of study drug
• •Life expectancy less than 6 months
• •Presence of any currently active AIDS defining conditions with the exception of stable cutaneous Kaposi's sarcoma
• •Treatment with proton-pump inhibitor or H2-receptor antagonist
• •ECG demonstrating atrioventricular block, prolonged QRS interval greater than 12 ms, or known complete bundle branch block
• •Acute or chronic hepatitis B infection as evidenced by presence of hepatitis B surface antigen and absence of hepatitis B surface antibody
• •Clinical or laboratory evidence of significantly decreased hepatic function of decompensation irrespective of liver enzyme levels
• •Prisoners or subjects who are involuntarily incarcerated
• •Subjects who are compulsorily detained for treatment of either a psychiatric or physical (e.g., infectious disease) illness